SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001123292-21-000143
Filing Date
2021-01-29
Accepted
2021-01-29 16:15:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 prevail13g_01262021.htm SC 13G 205298
  Complete submission text file 0001123292-21-000143.txt   206745
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Subject) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91049 | Film No.: 21571348
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 35 PARK LANE LONDON X0 W1K 1RB
Business Address 35 PARK LANE LONDON X0 W1K 1RB 44 20 7070 2550
JNE Partners LLP (Filed by) CIK: 0001770120 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SC 13G